A Phase 3 study with algenpantucel-L for patients with surgically resected pancreatic cancer, the IMPRESS (Immunotherapy for Pancreatic Resectable cancer Survival Study) study, is currently underway.
NewLink's lead product candidate, algenpantucel-L (HyperAcute pancreas), is being studied in a Phase 3 trial (IMPRESS: "Immunotherapy for Pancreatic Resectable cancer Survival Study") under a Special Protocol Assessment with the U.
Nineteen of the 20 patients with resectable cancer
completed therapy without interruption, and only one patient experienced a grade 3 gastrointestinal toxicity.
Unlike an immediate removal of the tumor, prolonged neoadjuvant therapy for resectable cancer
can be physically, socially, and emotionally difficult for patients, especially those with gynecologic malignancy.
When resectable cancer
cells can be removed by surgery, there is no evidence that the cancer has spread and the liver is working well.
Because the study analyzed patients with surgically resectable cancer
, it is possible that this marker panel will be diagnostically useful even for patients with small cancers.